Lyra Therapeutics Inc
Company Profile
Business description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company’s operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Contact
480 Arsenal Way
WatertownMA02472
USAT: +1 617 393-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
30
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,290.50 | 86.60 | 1.06% |
| CAC 40 | 7,573.76 | 37.50 | 0.50% |
| DAX 40 | 22,271.67 | 29.22 | 0.13% |
| Dow JONES (US) | 40,227.59 | 114.09 | 0.28% |
| FTSE 100 | 8,417.34 | 2.09 | 0.02% |
| HKSE | 21,998.86 | 26.90 | 0.12% |
| NASDAQ | 17,366.13 | 16.81 | -0.10% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,062.47 | 36.42 | -0.30% |
| S&P 500 | 5,528.75 | 3.54 | 0.06% |
| S&P/ASX 200 | 8,075.50 | 78.40 | 0.98% |
| SSE Composite Index | 3,287.45 | 0.96 | -0.03% |